医薬品の安全性とファーマコビジランスにおける AI クイズ

クイズに答えると、答えと解説が表示されます。

1. ファーマコビジランスの主な目標は何ですか?
   • 使用後の医薬品による危害の検出、評価、防止
   • 医師への新薬のマーケティング
   • 医薬品の小売価格の設定
   • 錠剤のパッケージデザイン
2. In the published n2c2 clinical NLP system, what information did the system extract from narrative notes?
   • Only patients’ handwritten signatures
   • Medication and adverse-event concepts and their relations
   • Only final regulatory decisions
   • Only medicine prices
3. 不均衡分析は有害事象データベースで何を検出しますか?
   • ブランド薬とジェネリック医薬品の価格差
   • 最も多くの報告書を提出した病院はどこですか
   • 薬物事象の組み合わせは統計上の偶然の予測よりも頻繁に報告される
   • 薬の使用期限について
4. What is VigiBase, according to Uppsala Monitoring Centre?
   • A database of randomized clinical-trial efficacy results only
   • A list of confirmed causal side effects for every medicine
   • A commercial catalogue of approved drug prices
   • The WHO global database of reported adverse events for medicines and vaccines
5. MedDRA はファーマコビジランス パイプラインで何に使用されますか?
   • 反応や状態をコーディングするための標準化された医学用語
   • 医薬品包装のブランド
   • 医師向けのスケジュール管理アプリ
   • MRIスキャナーの一種
6. Which sequence does UMC describe in its signal-management process?
   • Diagnosis, prescription, dispensing, billing and discharge
   • Detection, validation, prioritisation, assessment and communication
   • Data collection, automatic causality decision, recall and litigation
   • Model training, deployment, billing and marketing
7. How should a high disproportionality score in a spontaneous-report database be interpreted?
   • As a population incidence rate for all patients
   • As a confirmed causal adverse reaction
   • As a statistical signal for further assessment, not proof that the drug caused the event
   • As proof that no other factor contributed
8. Which four elements satisfy the minimum ICSR criteria in ICH E2D(R1)?
   • A confirmed causal link, a batch number, a prescriber signature, and a laboratory result
   • A product label, a randomized trial, a treatment response, and a safety committee vote
   • A hospital admission, a known dose, a genetic profile, and a published case report
   • An adverse event or other observation, a suspect or interacting product, an identifiable patient, and an identifiable reporter